Eversept Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Eversept Partners’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-797,694	Closed	-$3.14M	–	98
2021 Q4	$3.14M	Sell	797,694 -75,000	-9%	-$364K	0.2%	72
2021 Q3	$4.2M	Buy	872,694 +643,405	+281%	+$2.64M	0.29%	54
2021 Q2	$1.05M	Sell	229,289 -181,304	-44%	-$873K	0.07%	78
2021 Q1	$2.41M	Buy	+410,593	New	+$2.84M	0.12%	61

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eversept Partners's LXRX Position: Q1 2022 in Review

Eversept Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2022, closing a stake of 797,694 shares — an estimated $3.14M sold.

Eversept Partners first reported a position in LXRX in Q1 2021 and held it in 4 quarters. The position peaked at $4.2M in Q3 2021. 101 funds tracked by Wall St. Rank hold LXRX as of Q1 2022.

Eversept Partners reported no remaining Lexicon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Eversept Partners sold 797,694 Lexicon Pharmaceuticals shares in Q1 2022, an estimated $3.14M.
Eversept Partners first reported a position in Lexicon Pharmaceuticals in Q1 2021 and held it in 4 quarters.
Eversept Partners's Lexicon Pharmaceuticals position peaked at $4.2M in Q3 2021.
101 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2022.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.